Dr Kirsi Ketola
Position:
- Postdoctoral Fellow, University of British Columbia, Vancouver Prostate Centre
- U.S. Department of Defense Fellow
- Prostate Cancer Canada Postdoctoral Fellow
Biography:
Having trained in systems biology and medical biotechnology as well as in biochemistry and drug discovery, my current research interests include utilizing the knowledge of the “-omics” in designing novel treatment options for cancer and the use of state-of-the-art high-throughput technologies to identify novel targets and to repurpose old drugs for cancer treatment. My goal is also to find better ways to utilize current genome-wide technologies in designing personalized treatment options. Especially I am interested in the molecular mechanisms of treatment resistance including the activation of antioxidative defence mechanisms during drug induced epithelial-to-mesenchymal transition and accumulation of cancer stem cells. Currently, my projects focus on the mechanisms and targeting of castrate- and anti-androgen resistance, cell plasticity and neuroendocrine transdifferentiation in prostate cancer.
Best publications:
Ketola, K., Viitala, M., Kohonen, P., Fey, V., Culig, Z., Kallioniemi, O. Iljin, K., High-throughput cell-based compound screen identifies pinosylvin methyl ether and tanshinone IIA as inhibitors of castration-resistant prostate cancer, JMolBiochem 5(1), 2016
Ketola, K., Kallioniemi, O. Iljin, I. Chemical Biology Drug Sensitivity Screen Identifies Sunitinib as Synergistic Agent with Disulfiram in Prostate Cancer Cells, PloS one 2012;7(12):e51470.
Iljin, K., Ketola, K., Vainio, P., Halonen, P., Kohonen, P., Fey, V., Grafström, R.C., Perälä, M., Kallioniemi, O., High-throughput cell-based screening of 4910 known drugs and drug-like small molecules identifies disulfiram as an inhibitor of prostate cancer cell growth, Clin.Cancer Res., 2009, 15, 19, 6070-6078.
Ketola, K., Hilvo, M., Hyötyläinen, T., Vuoristo, A., Ruskeepää, A-L, Oresic, M., Kallioniemi, O. Iljin, K. Salinomycin Inhibits Prostate Cancer Growth and Migration via Induction of Oxidative Stress, Br J Cancer. 2012 Jan 3;106(1):99-106.
Ketola, K., Vainio, P., Fey, V., Kallioniemi, O. Iljin, I. Monensin Is a Potent Inducer of Oxidative Stress and Inhibitor of Androgen Signaling Leading to Apoptosis in Prostate Cancer Cells, MolCancer Ther; 2010 9(12); 3175–85.
Lehtinen, L., Ketola, K., Mpindi, J-P, Hilvo, M., Fey, V., Kallioniemi, O. Iljin, I. High-throughput Protein Lysate Screen Identifies Novel Vimentin Regulators in Breast Cancer, Oncotarget. 2013 Jan;4(1):48-63.
Ketola, K., Vuoristo, A., Oresic, M., Kallioniemi, O. Iljin, K. Monensin Induced Oxidative Stress Reduces Prostate Cancer Cell Migration and Cancer Stem Cell Population, Oxidative Stress and Diseases, Dr. Volodymyr Lushchak (Ed.), ISBN: 978-953-51-0552-7, InTech, 2012
https://www.researchgate.net/profile/Kirsi_Ketola
prostate cancer, treatment resistance, antioxidative defence mechanisms, gene expression, high-throughput screening, epithelial-to-mesenchymal transition, cancer stem cells.
